As of Oct 2017 Yossi BenAmram assumed responsibility as President of MSD EURAM (Europe, Russia, Africa and Middle East) region leading a $4B business covering more than 100 countries including Netherlands, Belgium, Switzerland, Austria, Greece, Israel, Russia, Turkey as well as the Middle East, Africa, Nordics, Baltics, CEE and Balkans clusters. Yossi also became a member of MSD international Leadership Team. Prior to his current position and from June 2016, Yossi led the Mid Europe region and served as a member of the European Leadership team.
From August of 2013 until May 2016 Yossi BenAmram has served as a senior vice president for Merck & Co., Inc. (known as MSD outside the U.S. and Canada) and as President of Merck’s Diversified Brands Customer Business Line (CBL). Yossi served on the Emerging Markets Leadership Team and as a member of the board of directors of SMSD (a joint venture of MSD and Simcere, of China). Yossi was tasked with P&L responsibility for Merck’s multi-billion USD off-patent originals portfolio of products spanning more than 10 different therapy areas and operational hubs in NJ-USA, Lucerne-Switzerland and Shanghai-China. In addition to designing the growth strategy for Merck’s Diversified Brands organization, Yossi oversaw the development of additional formulations and fix dose combinations for these brands; the operation of Merck’s Loss of Exclusivity Center of Excellence (COE) and the management of Merck’s Global Tender COE.
From August 2010 until August 2013, Yossi BenAmram served as vice president and general manager of Emerging Market (EM) operations. Yossi's team was tasked with the development of the EM strategy and Commercial Innovation initiatives, sales and marketing capability building, the design and execution of cross-divisional projects and the on-going collaboration between Merck’s Global Human Health Customer Business Lines and the Emerging Market Leadership Team. In that capacity, Yossi acted as the chair of the EM Chief Marketing Officers’ Forum and the cross-divisional Branded / Innovative Generics Operating Team [BGxOT] that was creating Merck's BGx/IGx product pipeline via the Merck's formulation labs in Holland and Mexico and the Merck/SUN joint venture (JV) in India.
Yossi's 29-year career in the pharmaceutical industry has spanned several positions and two companies. At Merck he was a member of Global Human Health (GHH) Bone, Respiratory, Immunology & Dermatology (BRID) franchise, served as a vice president and global brand leader for Respiratory products, global brand leader for SINGULAIR, and managing director of MSD in Israel. Prior to joining Merck in 1998, Yossi held several positions at TEVA Pharmaceuticals, Petach Tikva Israel. He holds an MBA and a B.A. in Economics and Management from the Recanati Graduate School of Business Administration, Tel Aviv University, Tel Aviv, Israel.